David Cunningham Owens
Research Subjects
David Cunningham Owens has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Eve C. Johnstone
Northwick Park Hospital, Harrow, Middlesex
5 shared publications - Stephen M. Lawrie
Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
5 shared publications Eve C. Johnstone
Division of Psychiatry, College of Medicine & Veterinary Medicine, The University of Edinburgh, Edinburgh, UK
4 shared publications- Andrew Mark McIntosh
Royal Infirmary Edinburgh
3 shared publications - Dominic E. Job
University of Edinburgh
2 shared publications - Heather Clare Whalley
Division of Psychiatry, University of Edinburgh, Edinburgh, UK
2 shared publications
Latest Publications
- Open Access
- 27 June 2025
- Published by Royal College of Psychiatrists in Bjpsych Bulletin
- Vol. 49 (6) , 437-438
Timothy John Crow, OBE, PhD, DPM, FRCP, FRCPsych, FMedSci
- 27 June 2025
- Published by Royal College of Psychiatrists in Bjpsych Bulletin
- Vol. 49 (6) , 437-438
Open AccessTimothy John Crow, OBE, PhD, DPM, FRCP, FRCPsych, FMedSci
- 17 April 2023
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 222 (5) , 221-222
The Rise and Fall of the Age of Psychopharmacology By Edward Shorter Oxford University Press. 2021. US$49.95 (pb). 352 pp. ISBN 9780197574430
- 17 April 2023
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 222 (5) , 221-222
The Rise and Fall of the Age of Psychopharmacology By Edward Shorter Oxford University Press. 2021. US$49.95 (pb). 352 pp. ISBN 9780197574430
- Open Access
- 13 June 2019
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 215 (3) , 516-518
Sodium valproate in psychiatric practice: time for a change in perception
Summary: Sodium valproate and related preparations have recently undergone regulatory review following concern about effects on the unborn child and doctors' failure to communicate risk. The issues are wider. Valproate is overused in psychiatry based on the false perception that ‘ease’ of use equates to better safety than alternatives. Valproic acid can disrupt fundamental physiological processes, the consequences of which are poorly understood and little discussed in the psychiatric literature. Valproate may be useful in a small number of patients with bipolar disorder but current prescribing patterns are unjustified. Perception needs to change.Declaration of interest: D.C.O. is psychiatric commissioner on the Commission on Human Medicines and a member of the European Medicines Agency's Scientific Advisory Group on Psychiatry. He chaired the European Medicines Agency's review of the psychiatric use of valproate in pregnancy and women of childbearing potential.
- 13 June 2019
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 215 (3) , 516-518
Open AccessSodium valproate in psychiatric practice: time for a change in perception
Summary: Sodium valproate and related preparations have recently undergone regulatory review following concern about effects on the unborn child and doctors' failure to communicate risk. The issues are wider. Valproate is overused in psychiatry based on the false perception that ‘ease’ of use equates to better safety than alternatives. Valproic acid can disrupt fundamental physiological processes, the consequences of which are poorly understood and little discussed in the psychiatric literature. Valproate may be useful in a small number of patients with bipolar disorder but current prescribing patterns are unjustified. Perception needs to change.Declaration of interest: D.C.O. is psychiatric commissioner on the Commission on Human Medicines and a member of the European Medicines Agency's Scientific Advisory Group on Psychiatry. He chaired the European Medicines Agency's review of the psychiatric use of valproate in pregnancy and women of childbearing potential.
- 17 December 2018
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 25 (1) , 57-69
Tardive dyskinesia update: the syndrome
SUMMARY: Tardive dyskinesia is a common iatrogenic neurological and neurobehavioural syndrome associated with the use of antidopaminergic medication, especially antipsychotics. Prior to the introduction of the newer antipsychotics in the 1990s, it was one of the major areas of psychiatric research but interest waned as the new drugs were reputed to have a reduced liability to extrapyramidal adverse effects in general, a claim now discredited by numerous pragmatic research studies. Early small-scale short-term prevalence studies were presented as evidence to support the assumption that patients on the newer drugs did indeed have a lower prevalence of tardive dyskinesia but recent large-scale review of studies with patients exposed for longer suggest that things have not changed. This article presents a clinical overview of a complex and varied syndrome in terms of its phenomenology, epidemiology and risk factors; a companion article will consider treatment. This overview aims to highlight tardive dyskinesia once again, especially to practitioners who have trained in an environment where this was considered mainly in historical terms.LEARNING OBJECTIVES: •Understand the complex phenomenology comprising the syndrome of tardive dyskinesia •Appreciate recent data on prevalence and incidence with the newer antipsychotics •Be aware of risk factors when recommending antipsychotic (and other antidopaminergic) drugs DECLARATION OF INTEREST: None.
- 17 December 2018
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 25 (1) , 57-69
Tardive dyskinesia update: the syndrome
SUMMARY: Tardive dyskinesia is a common iatrogenic neurological and neurobehavioural syndrome associated with the use of antidopaminergic medication, especially antipsychotics. Prior to the introduction of the newer antipsychotics in the 1990s, it was one of the major areas of psychiatric research but interest waned as the new drugs were reputed to have a reduced liability to extrapyramidal adverse effects in general, a claim now discredited by numerous pragmatic research studies. Early small-scale short-term prevalence studies were presented as evidence to support the assumption that patients on the newer drugs did indeed have a lower prevalence of tardive dyskinesia but recent large-scale review of studies with patients exposed for longer suggest that things have not changed. This article presents a clinical overview of a complex and varied syndrome in terms of its phenomenology, epidemiology and risk factors; a companion article will consider treatment. This overview aims to highlight tardive dyskinesia once again, especially to practitioners who have trained in an environment where this was considered mainly in historical terms.LEARNING OBJECTIVES: •Understand the complex phenomenology comprising the syndrome of tardive dyskinesia •Appreciate recent data on prevalence and incidence with the newer antipsychotics •Be aware of risk factors when recommending antipsychotic (and other antidopaminergic) drugs DECLARATION OF INTEREST: None.
- Open Access
- 1 December 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 202, 241-247
Is there a symptomatic distinction between the affective psychoses and schizophrenia? A machine learning approach
- 1 December 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 202, 241-247
Open AccessIs there a symptomatic distinction between the affective psychoses and schizophrenia? A machine learning approach
- 8 October 2018
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 25 (2) , 78-89
Tardive dyskinesia update: treatment and management
SUMMARY: The development of rational treatments for tardive dyskinesia has been held back by limitations to our understanding of its aetiology, which even now does not extend far beyond its association with centrally acting dopamine-blocking drugs. This article reviews briefly the major aetiological theories and addresses general management and specific treatment options. Primary prevention and early recognition remain the crucial management issues because, once the condition is established, there are no satisfactory treatments. The article considers two newly developed drugs, valbenazine and deutetrabenazine, in some detail as, although they are not yet licensed in Europe, they have largely been responsible for an upsurge in interest in tardive dyskinesia in the North American literature and are likely to be widely promoted in the future. Although possessed of undoubted benefits, the evidence suggests that these represent small steps rather than large leaps forward in treatment.LEARNING OBJECTIVES: •Be able to discuss the major aetiological theories on the causation of a common, and sometimes serious, adverse action of antidopaminergic drugs •Understand general management and specific treatment options •Understand the pharmacology and efficacy of two drugs recently approved by the FDA for the treatment of tardive dyskinesia DECLARATION OF INTEREST: D.C.O. is psychiatric commissioner on the Commission on Human Medicines, the UK drug regulator, and chair of its expert advisory group on CNS drugs. He is also a member of the psychiatry Scientific Advisory Group of the European Medicines Agency.
- 8 October 2018
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 25 (2) , 78-89
Tardive dyskinesia update: treatment and management
SUMMARY: The development of rational treatments for tardive dyskinesia has been held back by limitations to our understanding of its aetiology, which even now does not extend far beyond its association with centrally acting dopamine-blocking drugs. This article reviews briefly the major aetiological theories and addresses general management and specific treatment options. Primary prevention and early recognition remain the crucial management issues because, once the condition is established, there are no satisfactory treatments. The article considers two newly developed drugs, valbenazine and deutetrabenazine, in some detail as, although they are not yet licensed in Europe, they have largely been responsible for an upsurge in interest in tardive dyskinesia in the North American literature and are likely to be widely promoted in the future. Although possessed of undoubted benefits, the evidence suggests that these represent small steps rather than large leaps forward in treatment.LEARNING OBJECTIVES: •Be able to discuss the major aetiological theories on the causation of a common, and sometimes serious, adverse action of antidopaminergic drugs •Understand general management and specific treatment options •Understand the pharmacology and efficacy of two drugs recently approved by the FDA for the treatment of tardive dyskinesia DECLARATION OF INTEREST: D.C.O. is psychiatric commissioner on the Commission on Human Medicines, the UK drug regulator, and chair of its expert advisory group on CNS drugs. He is also a member of the psychiatry Scientific Advisory Group of the European Medicines Agency.
- 1 June 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 389, 4-9
Historical perspectives on tardive dyskinesia
- 1 June 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 389, 4-9
Historical perspectives on tardive dyskinesia
- Open Access
- 1 January 2018
- Published by SAGE Publications in Brain and Neuroscience Advances
- Vol. 2
The development of antipsychotic drugs
Antipsychotic drugs revolutionised psychiatric practice and provided a range of tools for exploring brain function in health and disease. Their development and introduction were largely empirical but based on long and honourable scientific credentials and remarkable powers of clinical observation. The class shares a common core action of attenuating central dopamine transmission, which underlies the major limitation to their use – high liability to disrupt extrapyramidal function – and also the most durable hypothesis of the basis of psychotic disorders, especially schizophrenia. However, the Dopamine Hypothesis, which has driven drug development for almost half a century, has become a straight-jacket, stifling innovation, resulting in a class of compounds that are largely derivative. Recent efforts only cemented this tendency as no clinical evidence supports the notion that newer compounds, modelled on clozapine, share that drug’s unique neurological tolerability and can be considered ‘atypical’. Patients and doctors alike must await a more profound understanding of central dopamine homeostasis and novel methods of maintaining it before they can again experience the intoxicating promise antipsychotics once held.
- 1 January 2018
- Published by SAGE Publications in Brain and Neuroscience Advances
- Vol. 2
Open AccessThe development of antipsychotic drugs
Antipsychotic drugs revolutionised psychiatric practice and provided a range of tools for exploring brain function in health and disease. Their development and introduction were largely empirical but based on long and honourable scientific credentials and remarkable powers of clinical observation. The class shares a common core action of attenuating central dopamine transmission, which underlies the major limitation to their use – high liability to disrupt extrapyramidal function – and also the most durable hypothesis of the basis of psychotic disorders, especially schizophrenia. However, the Dopamine Hypothesis, which has driven drug development for almost half a century, has become a straight-jacket, stifling innovation, resulting in a class of compounds that are largely derivative. Recent efforts only cemented this tendency as no clinical evidence supports the notion that newer compounds, modelled on clozapine, share that drug’s unique neurological tolerability and can be considered ‘atypical’. Patients and doctors alike must await a more profound understanding of central dopamine homeostasis and novel methods of maintaining it before they can again experience the intoxicating promise antipsychotics once held.
- 1 September 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (5) , 337-350
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 2)
Summary: This second of two articles on the ‘typical’ (‘first-generation’) antipsychotics covers non-phenothiazines: thioxanthenes (flupentixol and zuclopenthixol), butyrophenones/diphenylbutylpiperidines (including one-time world market-leader haloperidol, and pimozide) and sulpiride, for many years the only substituted benzamide available in the UK. Several tolerability issues ascribed specifically or more frequently to older antipsychotics are also discussed.
- 1 September 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (5) , 337-350
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 2)
Summary: This second of two articles on the ‘typical’ (‘first-generation’) antipsychotics covers non-phenothiazines: thioxanthenes (flupentixol and zuclopenthixol), butyrophenones/diphenylbutylpiperidines (including one-time world market-leader haloperidol, and pimozide) and sulpiride, for many years the only substituted benzamide available in the UK. Several tolerability issues ascribed specifically or more frequently to older antipsychotics are also discussed.
- 1 September 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (5) , 323-336
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 1)
Summary: A number of pragmatic trials have cast doubt on the concept of ‘atypicality’ in relation to antipsychotic drugs, and some commentators have argued that the dichotomy between ‘typical’ (‘first-generation’) and ‘atypical’ ('second-generation’) compounds is artificial and should be abandoned, leaving the entire class of antipsychotics available for consideration in more individualised treatment planning. However, younger psychiatrists now gain little or no experience in the use of older antipsychotics. This is the first of two articles addressing practical issues for consideration in prescribing the older antipsychotics available in the UK. It covers background, including the fundamental clinical action of antipsychotics, the nature of drug licensing and identification of pharmacological parameters that may be of value in prescribing decisions, and discusses the phenothiazines: chlorpromazine, promazine, levomepromazine, pericyazine, perphenazine, trifluoperazine and prochlorperazine.
- 1 September 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (5) , 323-336
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 1)
Summary: A number of pragmatic trials have cast doubt on the concept of ‘atypicality’ in relation to antipsychotic drugs, and some commentators have argued that the dichotomy between ‘typical’ (‘first-generation’) and ‘atypical’ ('second-generation’) compounds is artificial and should be abandoned, leaving the entire class of antipsychotics available for consideration in more individualised treatment planning. However, younger psychiatrists now gain little or no experience in the use of older antipsychotics. This is the first of two articles addressing practical issues for consideration in prescribing the older antipsychotics available in the UK. It covers background, including the fundamental clinical action of antipsychotics, the nature of drug licensing and identification of pharmacological parameters that may be of value in prescribing decisions, and discusses the phenothiazines: chlorpromazine, promazine, levomepromazine, pericyazine, perphenazine, trifluoperazine and prochlorperazine.